EUVIMEDEUVIMED entdecken
Crossref

22-PUB: Pharmacokinetics of RDSY1801 Enteric-Coated Capsules after Oral Administration in Dogs

WENBO JIN, JINGYI WANG, BEILIANG ZHANG, XIAOKANG LIU, YANMIN CHEN, YI LIU, WEIQUN SHEN

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-22-pub ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von WENBO JIN und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: RDSY1801 enteric-coated capsules effectively reduced postprandial hyperglycemia and HbA1c in diabetic dogs. This study was to evaluate the oral pharmacokinetics of RDSY1801 enteric-coated capsules in beagle dogs.

Methods

The pharmacokinetics of RDSY1801 were investigated in beagle dogs after intravenous, subcutaneous and oral administration. Plasma concentrations of RDSY1801 were analyzed using LC-MS/MS, and the pharmacokinetic parameters (Mean±SD) were generated using a non-compartmental model with WinNonlin software.

Results

The pharmacokinetics of RDSY1801 after intravenous injection (30 μg/kg, n=10) showed the mean Tmax of 0.083±0.001 hours, T1/2 of 0.076±0.028 hours, and Cmax of 103.68±14.30 ng/ml and AUCinf of 30.5±4.98 ng/ml*h, indicating the low volume of distribution and high clearance. The pharmacokinetics of RDSY1801 after subcutaneous injection (12 μg/kg) showed the mean Tmax of 0.83±0.26 hours, T1/2 of 0.94±0.55 hours, Cmax of 7.30±2.16 ng/ml, and the bioavailability was 86.36%. The oral pharmacokinetics of RDSY1801 enteric-coated capsules (1.2, 3, 12, 24, and 60 mg/dog, respectively) showed that Cmax was consistently achieved at about 3 hours (Tmax), and the Cmax and AUC increased linearly with escalating doses. The Cmax and AUC values ​​of male dogs were higher than those of female dogs at the same dose, and the calculated oral bioavailabilities were 2.62±0.52% in male dogs and 1.57±0.51% in female dogs.

Conclusion

RDSY1801 was able to enter the systemic circulation after an oral administration of RDSY1801 enteric-coated capsules although its oral bioavailability was low. Disclosure W. Jin: Employee; Current; Landing Laboratories. J. Wang: Employee; Current; Landing Laboratories. B. Zhang: Employee; Current; Landing Laboratories. X. Liu: Employee; Current; Landing Laboratories. Y. Chen: None. Y. Liu: Employee; Current; RxD Nova Pharmaceuticals, Inc. W. Shen: None.

Zitieren

APA

JIN, W., WANG, J., ZHANG, B., LIU, X., CHEN, Y., LIU, Y., & SHEN, W. (2026). 22-PUB: Pharmacokinetics of RDSY1801 Enteric-Coated Capsules after Oral Administration in Dogs. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-22-pub

Vancouver

JIN W, WANG J, ZHANG B, LIU X, CHEN Y, LIU Y, et al. 22-PUB: Pharmacokinetics of RDSY1801 Enteric-Coated Capsules after Oral Administration in Dogs. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-22-pub

BibTeX
@article{JIN2026,
  author = {JIN, WENBO and WANG, JINGYI and ZHANG, BEILIANG and LIU, XIAOKANG and CHEN, YANMIN and LIU, YI and SHEN, WEIQUN},
  title = {22-PUB: Pharmacokinetics of RDSY1801 Enteric-Coated Capsules after Oral Administration in Dogs},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-22-pub}
}
Kostenlos starten →